Skip to main content

Table 3 Regression analysis of left atrial function and measures of cardiac structure, function and serum biomarkers in the HCMnet cohort (N = 73)

From: Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy

 

LAPEmF

LAAEmF

LATEmF

LAVmin*

LAVbac*

LAVmax*

IVS

−0.88 (.18) <0.001

−0.28 (.19) 0.1

−0.70 (.20) 0.001

0.57 (.28) 0.046

0.85 (.36) 0.023

0.72 (.43) 0.097

LVEF

−0.088 (.18) 0.6

0.23 (.17) 0.2

−0.10 (.20) 0.6

−0.24 (.24) 0.3

−0.25 (.30) 0.4

−0.30 (.32) 0.4

LAVmin*

−0.007 (0.001) <0.001

−0.005 (0.0007) <0.001

−0.008 (0.0008) <0.001

–

–

–

LAVbac*

−0.005 (0.0007) <0.001

−0.002 (0.0007) 0.018

−0.005 (0.0008) <0.001

–

–

–

LAVmax*

−0.002 (.0008) 0.004

−0.002 (.0009) 0.058

−0.003 (.0009) 0.003

–

–

–

LVEDV

−0.004 (.040) 0.9

−0.034 (.043) 0.4

−0.023 (.039) 0.6

0.075 (.044) 0.092

0.11 (.059) 0.073

0.17 (.08) 0.027

LVESV

0.053 (.086) 0.5

−0.087 (.083) 0.3

−0.028 (.086) 0.7

0.14 (.10) 0.2

0.19 (.13) 0.1

0.32 (.16) 0.046

LV mass

−0.099 (.022) <0.001

0.002 (.026) 1.0

−0.060 (.025) 0.022

0.083 (.024) 0.001

0.13 (.03) <0.001

0.13 (.04) 0.001

Extent LGE

−0.43 (.20) 0.046

−0.55 (.24) 0.034

−0.74 (.22) 0.005

1.23 (.26) <0.001

1.35 (.33) <0.001

1.32 (.37) 0.002

Septal e’ (cm/s)

0.01 (.005) 0.067

−0.001 (.004) 0.8

0.005 (.004) 0.3

−0.77 (.40) 0.06

−1.20 (.55) 0.035

−1.09 (.73) 0.14

Septal e’/a’ ratio

0.04 (0.02) 0.13

−0.02 (.02) 0.3

0.008 (.01) 0.7

−0.31 (2.2) 0.9

−1.77 (2.9) 0.55

−1.8 (3.6) 0.6

Lateral e’ (cm/s)

0.004 (.005) 0.4

−0.001 (.003) 0.6

0.002 (.004) 0.6

−0.49 (.37) 0.19

−0.75 (.50) 0.14

−0.54 (.60) 0.4

Lateral e’/a’ ratio

0.004 (.02) 0.8

−0.02 (.008) 0.032

−0.008 (.01) 0.5

0.73 (1.2) 0.5

0.53 (1.9) 0.8

1.25 (2.4) 0.6

Global E’

0.97 (.48) 0.050

0.021 (.41) 1.0

0.64 (.47) 0.2

−1.02 (.48) 0.037

−1.50 (.54) 0.021

−1.39 (.77) 0.079

Log-NT-proBNP

−0.040 (.006) <0.001

−0.014 (.01) 0.16

−0.035 (.008) <0.001

3.55 (1.1) 0.002

4.53 (1.2) <0.001

3.99 (1.6) 0.013

Troponin I

2.1 (56) 1.0

−73 (48) 0.2

−78 (63) 0.2

146 (73) 0.069

130 (74) 0.1

86 (99) 0.4

MMP1

0.21 (.002) 0.5

0.10 (.21) 0.5

0.19 (.14) 0.2

−0.18 (0.20) 0.4

−0.27 (0.30) 0.4

−0.16 (0.44) 0.7

TIMP1

−0.002 (.005) 0.7

0.004 (.003) 0.2

0.004 (.004) 0.3

−0.005 (.005) 0.3

0.001 (.006) 0.3

0.008 (.007) 0.2

GAL3

0.24 (.46) 0.6

0.056 (.28) 0.049

0.53 (.36) 0.1

−0.50 (.30) 0.1

−0.60 (.43) 0.2

−0.83 (.55) 0.1

sST2

−0.21 (.10) 0.043

0.072 (.096) 0.5

−0.077 (.095) 0.4

−0.027 (.076) 0.7

−0.051 (.10) 0.6

−0.22 (.14) 0.1

  1. Reported as beta coefficient (SE) p-value in the regression model with left atrial function as the outcome (Y) and other echo, CMR and biomarker measures as predictor (X), adjusted for age, gender, BSA, and family relationship
  2. IVS interventricular septum thickness, LVEF left ventricular ejection fraction, LVEDV Left ventricular End Diastolic Volume, LVESV Left ventricular End Systolic Volume, LV left ventricular, LGE late gadolinium enhancement, E’ tissue Doppler early diastolic myocardial relaxation velocity, N-terminal pro-B-type natriuretic peptide (NT-proBNP); high sensitive troponin I (troponin I); matrix metalloproteinase-1 (MMP1); matrix metalloproteinase inhibitor-1 (TIMP1); galectin-3 (GAL3). *indexed to BSA
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us